Madrona Ventures anticipates a rise in private-to-private mergers as a key trend for 2026. With questions about the long-term durability of even fast-growing private AI companies, consolidation is seen as a primary way for winners to emerge and build more defensible businesses in a volatile market.

A successful acquisition strategy goes beyond the highest bid. It involves 'thinking like the molecule'—evaluating which buyer has the specific expertise, capabilities, and cultural alignment to best steward the asset's development. This reframes M&A from a financial transaction to a decision about the asset's future.

In a tight funding environment, a significant portion of startups now secure pharma partnerships *before* their Series A. This pre-validation has become a major draw for VCs, signaling a shift where corporate buy-in is needed to de-risk early-stage science for investors.

While staying private can offer strategic advantages, particularly for future M&A, the biotech industry lacks a mature private growth capital market. Companies needing hundreds of millions for late-stage trials have no choice but to go public, unlike their tech counterparts.

Private equity firms are again actively pursuing life sciences carve-outs and platform investments. Their characteristic speed and flexibility are pressuring corporate buyers, who now face increased competition and must adapt their own processes to compete effectively on deals.

Successful acquisitions don't just benefit the acquired company's investors. These investors often reinvest their profits into new, earlier-stage ventures, providing crucial capital that fuels the entire biotech ecosystem's growth and innovation.

Non-strategic capital is just a transaction. A strategic investor, however, becomes a partner who can accelerate growth through their network, expertise, and credibility. This alignment is critical because bringing on an investor is like a marriage; they must add more value than just their check.

Traditional venture funds have a mandate to distribute shares post-IPO. A crossover investor can credibly promise a founder, 'I never have to sell your stock to get paid. If you execute, I can hold you forever.' This aligns the investor with the founder's long-term vision and offers stability.

The adage 'biotech companies are bought, not sold' means an acquisition is typically not the result of a company actively seeking a buyer. As with Portola's sale to Alexion, it is often a fiduciary responsibility to consider an unsolicited offer, even if the internal plan is independent growth.